Historically A Disappointment, Neuroprotective Drug Strategies Pursuing New Targets And Mechanisms

Main Category: Neurology / Neuroscience
Also Included In: Alzheimer's / Dementia;  Seniors / Aging
Article Date: 13 May 2008 - 1:00 PDT

email to a friend   printer friendly   opinions  

In terms of the number of people affected, neurological diseases that contributed to decline in neuronal function are sometimes considered the newest healthcare epidemic. With the number of cases of neurodegenerative conditions expected to grow dramatically, driven by the aging population in developed countries, this therapeutic area represents one of the most compelling in both commercial and human terms. But the past few decades have been marked by optimistic pronouncements followed by clinical disappointments. As advances in genetics and target identification increase our understanding of the physiological basis of disease and cellular medicine, the search for a solution to neuronal protection is reaching into new clinical areas.

While it is sometimes difficult to distinguish the true level of activity in this noisy pharmacologic environment where terms such as 'may' and 'might' have become ubiquitous, our research has identified more than two dozen companies that are actively pursuing therapeutic programs specifically targeting neuroprotection. The therapeutic approaches are as diverse as the companies themselves, and include cell signal modulation, cellular mobility, immunosuppression, receptor antagonists and ion channel strategies. These companies are attempting to address a healthcare segment that is enormous in terms of financial and emotional costs.

These developments are examined in a new and comprehensive report - Neuroprotective Therapeutics: Drugs, Developments and Prospects. The report analyzes the current generation of neuroprotective candidates and their probable impact on treatment options and the competitive landscape.

More information is also available at www.applieddata.org .

About Applied Data

Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

• Additional
• References
• Citations